BARD Score for NAFLD Fibrosis
BMI, AST/ALT Ratio, and Diabetes (BARD) score predicts advanced fibrosis (F3-F4) in NAFLD. Score ≥2 has 96% negative predictive value for advanced fibrosis.
Score interpretation
BARD 0–1 — 96% negative predictive value for advanced fibrosis (F3–F4)
→ Advanced fibrosis unlikely; lifestyle modification; reassess in 1–2 years
BARD ≥2 — associated with 17× increased odds of advanced fibrosis. Positive predictive value ~43%.
→ Further assessment needed; FIB-4, FibroScan (transient elastography) or liver biopsy; hepatology referral
Interpretation bands for the BARD Score. Apply clinical judgement and local guidance.
References
- Harrison SA et al. A simple and accurate clinical scoring system for NAFLD. Hepatology. 2008;47(6):1919–1926.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Acute Liver Failure · EASL 2017 / BSG
- Decompensated Cirrhosis · BSG 2015 / EASL 2018
- IBD Acute Flare Assessment · ECCO / BSG 2019
- Hepatitis B Management · EASL 2017 / NICE NG33
- Dysphagia Assessment Pathway · BSG 2010 / NICE NG12
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.